MedaSorb Technologies - 500 Beiträge pro Seite
eröffnet am 24.08.06 14:11:24 von
neuester Beitrag 14.06.07 18:34:42 von
neuester Beitrag 14.06.07 18:34:42 von
Beiträge: 15
ID: 1.078.778
ID: 1.078.778
Aufrufe heute: 0
Gesamt: 5.288
Gesamt: 5.288
Aktive User: 0
ISIN: US23283X2062 · WKN: A12GDU · Symbol: CTSO
0,8760
EUR
+2,52 %
+0,0215 EUR
Letzter Kurs 28.03.24 Quotrix Düsseldorf
Neuigkeiten
01.09.23 · globenewswire |
31.08.23 · globenewswire |
01.08.23 · globenewswire |
26.07.23 · globenewswire |
Werte aus der Branche Gesundheitswesen
Wertpapier | Kurs | Perf. % |
---|---|---|
1,2000 | +99.999,00 | |
1,5050 | +99,58 | |
5,5000 | +22,22 | |
14,492 | +22,09 | |
0,9335 | +18,46 |
Wertpapier | Kurs | Perf. % |
---|---|---|
2,1400 | -20,59 | |
0,5800 | -29,29 | |
0,9750 | -33,45 | |
17,050 | -50,44 | |
16,550 | -67,06 |
www.medasorb.com
RedChip Visibility Initiates Research On MedaSorb Technologies
2006-08-22 13:49 ET - News Release
ORLANDO, Fla., Aug. 22, 2006 (PRIMEZONE) -- RedChip Visibility, a division of RedChip Companies, announced today that they have initiated research on MedaSorb Technologies (OTCBB:MSBT).
Patrick Murphy, CFA, RedChip Research Analyst, wrote in the report:
"We believe it is reasonable to expect that MedaSorb will get its products to market in the time frame projected by management, and that the upside potential is more than sufficient to justify the many risks associated with an investment today. Assuming CytoSorbT (MedaSorb's primary product which is used in the treatment of the symptoms associated with sepsis, cardiopulmonary bypass surgery, organ donation transplantation, and drug overdoses.) makes it to market in 3 years, MedaSorb will be worth at least $375 million, 3 years from now."
To receive a complimentary copy of the RedChip Research Report for MSBT, please visit: http://www.redchip.com/visibility/about.asp?page=requestMSBT…
About RedChip Visibility(tm)
RedChip Visibility, a division of RedChip Companies Inc., writes fundamental research on small-cap companies. RedChip's success has been documented in Forbes, Barron's and the Wall Street Journal. RedChip Visibility(tm) provides small-cap companies access to both professional and individual small-cap investors by holding conferences throughout the United States, producing online corporate visibility programs, and writing company sponsored research.
The RedChip Companies Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2761
RedChip Visibility Research Disclosure
Any opinions expressed herein are subject to change. RedChip Companies Inc. is an affiliate of the Aurelius Consulting Group, Inc. MedaSorb Technologies, Inc. is a client of the Aurelius Consulting Group, Inc. and of RedChip Visibility, a division of RedChip Companies. MSBT paid RedChip Visibility $34,200 for the RedChip Visibility Research Program, which includes this report. RedChip Visibility, a division of RedChip Companies, Inc., and the Aurelius Consulting Group Inc., in a joint marketing agreement, have been contracted by MedaSorb Technologies, Inc. to increase investor awareness of MSBT to the small-cap equity community. These services may include investor conferences and digital and print distribution of MSBT investor related materials. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the Aurelius Consulting Group is an investor relations firm hired by the Company and receives a monthly fee of $9,500.
CONTACT: RedChip Companies
1-800-REDCHIP
info@redchip.com
www.redchip.com
Quelle: http://www.stockwatch.com/swnet/newsit/newsit_newsit.aspx?bi…
Industry: Medical Laboratories & Research
Shares Outstanding: 7,855,000
Market Cap: 19,244,750
Sollte MedaSorb erfolg haben, wird es duch den Verkauf von CytoSorb mehrere Milliarden Dollar/Jahr erwirtschaften.
On September 1, 2006, the United States District Court for The Eastern District Of Pennsylvania approved a Stipulated Order and Settlement Agreement (the “Settlement Agreement” ) under which MedaSorb Technologies Corporation (“MedaSorb” ) and Purolite International Ltd. and its affiliates (“Purolite” ) agreed to the settlement of the action that had been commenced by Purolite in which Purolite claimed ownership rights in certain of MedaSorb’s patents. The Settlement Agreement provides MedaSorb with the exclusive right to use its patented technology and proprietary know how relating to adsorbent polymers for a period of 18 years. Under the terms of the Settlement Agreement, MedaSorb has agreed to pay Purolite royalties of 2.5% to 5% on the sale of certain of its products if and when those products are sold commercially. A copy of the Settlement Agreement is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Quelle: http://app.quotemedia.com/quotetools/showFilingOutline.go?sy…
Quelle: http://app.quotemedia.com/quotetools/showFilingOutline.go?sy…
MedaSorb Announces That They Intend to File Investigational Device Exemption With the FDATuesday September 19, 1:22 pm ET
MONMOUTH JUNCTION, N.J., Sept. 19, 2006 (PRIMEZONE) -- MedaSorb Technologies, Inc. (OTC BB: MSBT.OB) announced today that they intend to file an Investigational Device Exemption (IDE) with the FDA by the end of the year for CytoSorb(tm)'s Drug Detoxification indication. The Company is in contact with the FDA regarding an informal guidance meeting to confirm its approach for testing and development of the indication while preparing the final documentation for the submission. MedaSorb is confident the performance of CytoSorb(tm)'s adsorbent bead technology for Drug Detoxification is superior to current charcoal filter technology for removing drugs toxins from the blood stream in overdose traumas. MedaSorb anticipates this will be the first indication to achieve 510K approval for CytoSorb(tm).
The Company is pleased with the progress they are making in regards to their Sepsis Treatment indication. MedaSorb believes that CytoSorb(tm) will be an important adjunct to the current treatment of Sepsis. Sepsis is an out of control inflammatory response that attacks the infecting organism but also damages the patient and leaves the immune system weakened; by removing the excess cytokines produced by the inflammatory response, the company believes, CytoSorb(tm) improves the chances of survival and speed of recovery for the patient. There are 750,000 sepsis cases and 250,000 sepsis related deaths in the U.S. annually. MedaSorb expects to file their IDE for the treatment of Sepsis by the end of the 1st quarter 2007. They are currently conducting meetings with their Medical Advisory Board to complete a detailed clinical trail protocol for delivery to the FDA as part of their IDE submission. The company anticipates the commencement of clinical trials for Sepsis in the second half of 2007.
Al Kraus, the President and CEO of MedaSorb said, ``The Company is working diligently with our scientific staff, the Medical Advisory Board and the FDA to submit our filings for both Drug Detoxification and Sepsis indications for CytoSorb(tm) as expected. The company has sufficient resources to commence the Sepsis clinical trails, and we are excited about moving forward on both indications.''
About MedaSorb Technologies
MedaSorb Technologies Corporation is a medical device company headquartered in Monmouth Junction, New Jersey. MedaSorb has developed and is preparing to commercialize a blood purification technology that efficiently removes toxic compounds from circulating blood.
MedaSorb's initial products (CytoSorb(tm) and BetaSorb(tm)) are known medically as hemoperfusion devices and incorporate proprietary adsorbent polymer technology. MedaSorb believes that potential healthcare applications for its products include: -- adjunctive treatment and/or prevention of sepsis; -- prevention of damage to organs donated for transplant prior to organ harvest; -- prevention of post-operative complications of cardiac surgery; -- short and long-term treatment of kidney failure; and drug detoxification.
MedaSorb's management team is led by Al Kraus, now the Company's President and Chief Executive Officer, who has more than twenty-five years' experience managing companies in the dialysis, medical device products, personal computer and custom software industries. Other members of MedaSorb's management team, who are now officers of the Company, include James Winchester, MD the Company's Chief Medical Officer, Vincent Capponi the Company's Chief Operating Officer, and David Lamadrid, the Company's Chief Financial Officer.
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. MedaSorb Technologies Corporation believes that its primary risk factors include, but are not limited to: ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; obtaining government approvals, including required FDA approvals; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Current Report on Form 8-K filed with the SEC on July 6, 2006, which is available at http://www.sec.gov
For Further Information, Contact:
Dave Gentry, Aurelius Consulting Group, Inc., Century Bank Building,
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (407) 644-4256,
Fax: (407) 644-0758, info@aurcg.com
MONMOUTH JUNCTION, N.J., Sept. 19, 2006 (PRIMEZONE) -- MedaSorb Technologies, Inc. (OTC BB: MSBT.OB) announced today that they intend to file an Investigational Device Exemption (IDE) with the FDA by the end of the year for CytoSorb(tm)'s Drug Detoxification indication. The Company is in contact with the FDA regarding an informal guidance meeting to confirm its approach for testing and development of the indication while preparing the final documentation for the submission. MedaSorb is confident the performance of CytoSorb(tm)'s adsorbent bead technology for Drug Detoxification is superior to current charcoal filter technology for removing drugs toxins from the blood stream in overdose traumas. MedaSorb anticipates this will be the first indication to achieve 510K approval for CytoSorb(tm).
The Company is pleased with the progress they are making in regards to their Sepsis Treatment indication. MedaSorb believes that CytoSorb(tm) will be an important adjunct to the current treatment of Sepsis. Sepsis is an out of control inflammatory response that attacks the infecting organism but also damages the patient and leaves the immune system weakened; by removing the excess cytokines produced by the inflammatory response, the company believes, CytoSorb(tm) improves the chances of survival and speed of recovery for the patient. There are 750,000 sepsis cases and 250,000 sepsis related deaths in the U.S. annually. MedaSorb expects to file their IDE for the treatment of Sepsis by the end of the 1st quarter 2007. They are currently conducting meetings with their Medical Advisory Board to complete a detailed clinical trail protocol for delivery to the FDA as part of their IDE submission. The company anticipates the commencement of clinical trials for Sepsis in the second half of 2007.
Al Kraus, the President and CEO of MedaSorb said, ``The Company is working diligently with our scientific staff, the Medical Advisory Board and the FDA to submit our filings for both Drug Detoxification and Sepsis indications for CytoSorb(tm) as expected. The company has sufficient resources to commence the Sepsis clinical trails, and we are excited about moving forward on both indications.''
About MedaSorb Technologies
MedaSorb Technologies Corporation is a medical device company headquartered in Monmouth Junction, New Jersey. MedaSorb has developed and is preparing to commercialize a blood purification technology that efficiently removes toxic compounds from circulating blood.
MedaSorb's initial products (CytoSorb(tm) and BetaSorb(tm)) are known medically as hemoperfusion devices and incorporate proprietary adsorbent polymer technology. MedaSorb believes that potential healthcare applications for its products include: -- adjunctive treatment and/or prevention of sepsis; -- prevention of damage to organs donated for transplant prior to organ harvest; -- prevention of post-operative complications of cardiac surgery; -- short and long-term treatment of kidney failure; and drug detoxification.
MedaSorb's management team is led by Al Kraus, now the Company's President and Chief Executive Officer, who has more than twenty-five years' experience managing companies in the dialysis, medical device products, personal computer and custom software industries. Other members of MedaSorb's management team, who are now officers of the Company, include James Winchester, MD the Company's Chief Medical Officer, Vincent Capponi the Company's Chief Operating Officer, and David Lamadrid, the Company's Chief Financial Officer.
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. MedaSorb Technologies Corporation believes that its primary risk factors include, but are not limited to: ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; obtaining government approvals, including required FDA approvals; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Current Report on Form 8-K filed with the SEC on July 6, 2006, which is available at http://www.sec.gov
For Further Information, Contact:
Dave Gentry, Aurelius Consulting Group, Inc., Century Bank Building,
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (407) 644-4256,
Fax: (407) 644-0758, info@aurcg.com
10/27/2006
MONMOUTH JUNCTION, N.J., Oct 27, 2006 (PrimeZone Media Network via COMTEX News Network) --
MedaSorb Technologies (OTCBB:MSBT) announced today that it has acquired ownership of Patent No. 6,884,829 from Robert Albright, Ph.D., a scientific consultant to the Company, in the completion of a prearranged agreement. The patent covers important chemistry for the production and efficacy of the company's adsorbent technology which is the cornerstone of the both the BetaSorb(tm) and CytoSorb(tm) products. The technology includes the identification of a number of dispersants that can be utilized in the manufacturing process to simultaneously form the external hemocompatible coating and the adsorbent polymer in a single step. This process further strengthens MedaSorb's intellectual property portfolio and could significantly reduce both the time and cost of manufacturing the CytoSorb(tm) polymer.
Al Kraus, the CEO of MedaSorb, said, "We are pleased to complete the assignment of this important patent to our intellectual property portfolio. As the company moves towards FDA approval for our CytoSorb(tm) product, we look to benefit from the cost and time savings this technology offers us in the manufacturing process."
About MedaSorb Technologies, Inc.
MedaSorb Technologies Corporation is a medical device company headquartered in Monmouth Junction, New Jersey. MedaSorb has developed and is preparing to commercialize a blood purification technology that efficiently removes toxic compounds from circulating blood.
MedaSorb's initial products (CytoSorb(tm) and BetaSorb(tm)) are known medically as hemoperfusion devices and incorporate proprietary adsorbent polymer technology. MedaSorb believes that potential healthcare applications for its products include: -- adjunctive treatment and/or prevention of sepsis; -- prevention of damage to organs donated for transplant prior to organ harvest; -- prevention of post-operative complications of cardiac surgery; -- short and long-term treatment of kidney failure; and drug detoxification.
MedaSorb's management team is led by Al Kraus, President and CEO, who has more than twenty-five years' experience managing companies in the dialysis, medical device products, personal computer and custom software industries. Other members of MedaSorb's management team include James Winchester, MD, CMO; Vincent Capponi, COO; and David Lamadrid, CFO.
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. MedaSorb Technologies Corporation believes that its primary risk factors include, but are not limited to: ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; obtaining government approvals, including required FDA approvals; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Current Report on Form 8-K filed with the SEC on July 6, 2006, which is available at www.sec.gov
This news release was distributed by PrimeZone, www.primezone.com
SOURCE: MedaSorb Technologies
Incline Partners, LLC Andrew J. Deniken (646) 216-8847 ajd@inclinepartners.net Aurelius Consulting Group, Inc. Bill Miller (407) 644-4256 ext. 113 bill@aurcg.com www.runonideas.com
(C) Copyright 2006 PrimeZone Media Network, Inc. All rights reserved.
MONMOUTH JUNCTION, N.J., Oct 27, 2006 (PrimeZone Media Network via COMTEX News Network) --
MedaSorb Technologies (OTCBB:MSBT) announced today that it has acquired ownership of Patent No. 6,884,829 from Robert Albright, Ph.D., a scientific consultant to the Company, in the completion of a prearranged agreement. The patent covers important chemistry for the production and efficacy of the company's adsorbent technology which is the cornerstone of the both the BetaSorb(tm) and CytoSorb(tm) products. The technology includes the identification of a number of dispersants that can be utilized in the manufacturing process to simultaneously form the external hemocompatible coating and the adsorbent polymer in a single step. This process further strengthens MedaSorb's intellectual property portfolio and could significantly reduce both the time and cost of manufacturing the CytoSorb(tm) polymer.
Al Kraus, the CEO of MedaSorb, said, "We are pleased to complete the assignment of this important patent to our intellectual property portfolio. As the company moves towards FDA approval for our CytoSorb(tm) product, we look to benefit from the cost and time savings this technology offers us in the manufacturing process."
About MedaSorb Technologies, Inc.
MedaSorb Technologies Corporation is a medical device company headquartered in Monmouth Junction, New Jersey. MedaSorb has developed and is preparing to commercialize a blood purification technology that efficiently removes toxic compounds from circulating blood.
MedaSorb's initial products (CytoSorb(tm) and BetaSorb(tm)) are known medically as hemoperfusion devices and incorporate proprietary adsorbent polymer technology. MedaSorb believes that potential healthcare applications for its products include: -- adjunctive treatment and/or prevention of sepsis; -- prevention of damage to organs donated for transplant prior to organ harvest; -- prevention of post-operative complications of cardiac surgery; -- short and long-term treatment of kidney failure; and drug detoxification.
MedaSorb's management team is led by Al Kraus, President and CEO, who has more than twenty-five years' experience managing companies in the dialysis, medical device products, personal computer and custom software industries. Other members of MedaSorb's management team include James Winchester, MD, CMO; Vincent Capponi, COO; and David Lamadrid, CFO.
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. MedaSorb Technologies Corporation believes that its primary risk factors include, but are not limited to: ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; obtaining government approvals, including required FDA approvals; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Current Report on Form 8-K filed with the SEC on July 6, 2006, which is available at www.sec.gov
This news release was distributed by PrimeZone, www.primezone.com
SOURCE: MedaSorb Technologies
Incline Partners, LLC Andrew J. Deniken (646) 216-8847 ajd@inclinepartners.net Aurelius Consulting Group, Inc. Bill Miller (407) 644-4256 ext. 113 bill@aurcg.com www.runonideas.com
(C) Copyright 2006 PrimeZone Media Network, Inc. All rights reserved.
Übersetzt mit Opera
MedaSorb Technologien (OTCBB:MSBT) verkündeten heute, daß es Besitz
des Patents Nr. 6.884.829 von Robert Albright, Ph.D., ein
wissenschaftlicher Berater zur Firma erworben hat, in der Beendigung
einer vorarrangierten Vereinbarung. Das Patent umfaßt wichtige Chemie
für die Produktion und Wirksamkeit der Adsorbenttechnologie der
company\s, die der Grundstein der BetaSorb(tm) und CytoSorb(tm)
Produkte ist. Die Technologie schließt die Kennzeichnung einer Anzahl
von Dispersionsmitteln ein, die im Herstellungsverfahren verwendet
werden können, um die externe hemocompatible Schicht und das
Adsorbentpolymer-Plastik in einem Einzelschritt gleichzeitig zu
bilden. Dieser weitere Prozeß verstärkt MedaSorb\s Mappe des
geistigen Eigentums und könnte die Zeit und die Kosten Produktion des
CytoSorb(tm) Polymer-Plastiks erheblich verringern.
Al Kraus, der CEO von MedaSorb, gesagt, "wir freuen uns, die Anweisung
dieses wichtigen Patents zu unserer Mappe des geistigen Eigentums
durchzuführen. Während die Firma in Richtung zur FDA-Zustimmung für
unser CytoSorb(tm) Produkt umzieht, schauen wir, um von den Kosten zu
profitieren und Zeitsparungen diese Technologie bietet uns im
Herstellungsverfahren."an
Über MedaSorb Technologien Inc..
MedaSorb Technologies Corporation ist medizinische Vorrichtung Firma,
die in der Monmouth Verzweigung, Neu-Jersey gehabt wird. MedaSorb hat
entwickelt und vorbereitet, eine Blutreinigungtechnologie in den
Handel zu bringen, die leistungsfähig giftige Mittel von verteilendem
Blut entfernt.
MedaSorb\s Ausgangsprodukte (CytoSorb(tm) und BetaSorb(tm)) bekannt
medizinisch als hemoperfusion Vorrichtungen und enthalten eigene
Adsorbentpolymer-Plastik Technologie. MedaSorb glaubt, daß mögliche
healthcare Anwendungen für seine Produkte einschließen: --
adjunctive Behandlung und/oder Verhinderung von sepsis; --
Verhinderung der Beschädigung der Organe gespendet für Transplant
vor Organernte; -- Verhinderung der postoperativen Komplikationen der
Herzchirurgie; -- kurze und langfristige Behandlung des Niereausfalls;
und Drogeentgiftung.
Managementmannschaft MedaSorb\s wird von Al Kraus, Präsident und CEO
geführt, der mehr als fünfundzwanzig Jahre \ ' Erfahrung handhabende
Firmen in der Dialyse, medizinischen in den Vorrichtung Produkten, PC
in und in den Softwareindustrien hat. Andere Mitglieder der
Managementmannschaft MedaSorb\s schließen James Winchester, MD, CMO
mit ein; Vincent Capponi, GURREN; und David Lamadrid, CFO.
Gruß
Typhoon
MedaSorb Technologien (OTCBB:MSBT) verkündeten heute, daß es Besitz
des Patents Nr. 6.884.829 von Robert Albright, Ph.D., ein
wissenschaftlicher Berater zur Firma erworben hat, in der Beendigung
einer vorarrangierten Vereinbarung. Das Patent umfaßt wichtige Chemie
für die Produktion und Wirksamkeit der Adsorbenttechnologie der
company\s, die der Grundstein der BetaSorb(tm) und CytoSorb(tm)
Produkte ist. Die Technologie schließt die Kennzeichnung einer Anzahl
von Dispersionsmitteln ein, die im Herstellungsverfahren verwendet
werden können, um die externe hemocompatible Schicht und das
Adsorbentpolymer-Plastik in einem Einzelschritt gleichzeitig zu
bilden. Dieser weitere Prozeß verstärkt MedaSorb\s Mappe des
geistigen Eigentums und könnte die Zeit und die Kosten Produktion des
CytoSorb(tm) Polymer-Plastiks erheblich verringern.
Al Kraus, der CEO von MedaSorb, gesagt, "wir freuen uns, die Anweisung
dieses wichtigen Patents zu unserer Mappe des geistigen Eigentums
durchzuführen. Während die Firma in Richtung zur FDA-Zustimmung für
unser CytoSorb(tm) Produkt umzieht, schauen wir, um von den Kosten zu
profitieren und Zeitsparungen diese Technologie bietet uns im
Herstellungsverfahren."an
Über MedaSorb Technologien Inc..
MedaSorb Technologies Corporation ist medizinische Vorrichtung Firma,
die in der Monmouth Verzweigung, Neu-Jersey gehabt wird. MedaSorb hat
entwickelt und vorbereitet, eine Blutreinigungtechnologie in den
Handel zu bringen, die leistungsfähig giftige Mittel von verteilendem
Blut entfernt.
MedaSorb\s Ausgangsprodukte (CytoSorb(tm) und BetaSorb(tm)) bekannt
medizinisch als hemoperfusion Vorrichtungen und enthalten eigene
Adsorbentpolymer-Plastik Technologie. MedaSorb glaubt, daß mögliche
healthcare Anwendungen für seine Produkte einschließen: --
adjunctive Behandlung und/oder Verhinderung von sepsis; --
Verhinderung der Beschädigung der Organe gespendet für Transplant
vor Organernte; -- Verhinderung der postoperativen Komplikationen der
Herzchirurgie; -- kurze und langfristige Behandlung des Niereausfalls;
und Drogeentgiftung.
Managementmannschaft MedaSorb\s wird von Al Kraus, Präsident und CEO
geführt, der mehr als fünfundzwanzig Jahre \ ' Erfahrung handhabende
Firmen in der Dialyse, medizinischen in den Vorrichtung Produkten, PC
in und in den Softwareindustrien hat. Andere Mitglieder der
Managementmannschaft MedaSorb\s schließen James Winchester, MD, CMO
mit ein; Vincent Capponi, GURREN; und David Lamadrid, CFO.
Gruß
Typhoon
MedaSorb Technologies Corporation Files New Patent Application
2006-11-13 08:49 ET - News Release
MONMOUTH JUNCTION, N.J., Nov. 13, 2006 (PRIMEZONE) -- MedaSorb Technologies Corporation (OTCBB:MSBT) announced today that it has filed a new patent application covering its Ultra Select(tm) polymer technology. This new technology extends MedaSorb's line of products that are in the process of commercialization. The polymer is being developed for use with medical applications requiring long term use and extended treatment times, such as nightly dialysis. MedaSorb believes that its Ultra Select(tm) polymer is highly selective in extracting only midsize proteins, such as cytokines and B2-microglobulin, from blood and other physiologic fluids, while keeping the components required for good health such as cells, platelets, albumin, hemoglobin, fibrinogen, and other serum proteins intact. This patent application, once approved, will further strengthen MedaSorb's intellectual property portfolio.
Al Kraus the CEO of MedaSorb said, "MedaSorb is excited to complete this important new patent application. We believe our next generation products will benefit from this new selective polymer. We expect to use Ultra Select(tm) as an addition to our BetaSorb(tm) line of products, to provide enhanced treatment options for end stage renal patients. Additionally, we continue to focus on the upcoming FDA filings for our CytoSorb(tm) product for both the sepsis and drug detoxicification indications."
About MedaSorb
MedaSorb Technologies Corporation is a medical device company headquartered in Monmouth Junction, New Jersey. MedaSorb is a development stage company that has developed and is preparing to commercialize a blood purification technology that efficiently removes toxic compounds from circulating blood.
MedaSorb's initial products (CytoSorb(tm) and BetaSorb(tm)), are known medically as hemoperfusion devices and incorporate proprietary adsorbent polymer technology. MedaSorb believes that potential healthcare applications for its products include: adjunctive treatment and/or prevention of sepsis; prevention of damage to organs donated for transplant prior to organ harvest; prevention of post-operative complications of cardiac surgery; short and long-term treatment of kidney failure; and drug detoxification.
MedaSorb's management team is led by Al Kraus, President and CEO, who has more than twenty-five years' experience managing companies in the dialysis, medical device products, personal computer and custom software industries. Other members of MedaSorb's management team include James Winchester, MD, CMO, Vincent Capponi, COO, and David Lamadrid, CFO.
Forward Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. MedaSorb Technologies Corporation believes that its primary risk factors include, but are not limited to: ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; obtaining government approvals, including required FDA approvals; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Current Report on Form 8-K filed with the SEC on July 6, 2006, which is available at www.sec.gov
CONTACT: Incline Partners, LLC
Andrew J. Deniken
(646) 216-8847
ajd@inclinepartners.net
RedChip Companies/Aurelius Consulting, Inc.
Bill Miller
(407) 644-4256, ext. 113
bill@aurcg.com
www.runonideas.com
www.redchip.com
2006-11-13 08:49 ET - News Release
MONMOUTH JUNCTION, N.J., Nov. 13, 2006 (PRIMEZONE) -- MedaSorb Technologies Corporation (OTCBB:MSBT) announced today that it has filed a new patent application covering its Ultra Select(tm) polymer technology. This new technology extends MedaSorb's line of products that are in the process of commercialization. The polymer is being developed for use with medical applications requiring long term use and extended treatment times, such as nightly dialysis. MedaSorb believes that its Ultra Select(tm) polymer is highly selective in extracting only midsize proteins, such as cytokines and B2-microglobulin, from blood and other physiologic fluids, while keeping the components required for good health such as cells, platelets, albumin, hemoglobin, fibrinogen, and other serum proteins intact. This patent application, once approved, will further strengthen MedaSorb's intellectual property portfolio.
Al Kraus the CEO of MedaSorb said, "MedaSorb is excited to complete this important new patent application. We believe our next generation products will benefit from this new selective polymer. We expect to use Ultra Select(tm) as an addition to our BetaSorb(tm) line of products, to provide enhanced treatment options for end stage renal patients. Additionally, we continue to focus on the upcoming FDA filings for our CytoSorb(tm) product for both the sepsis and drug detoxicification indications."
About MedaSorb
MedaSorb Technologies Corporation is a medical device company headquartered in Monmouth Junction, New Jersey. MedaSorb is a development stage company that has developed and is preparing to commercialize a blood purification technology that efficiently removes toxic compounds from circulating blood.
MedaSorb's initial products (CytoSorb(tm) and BetaSorb(tm)), are known medically as hemoperfusion devices and incorporate proprietary adsorbent polymer technology. MedaSorb believes that potential healthcare applications for its products include: adjunctive treatment and/or prevention of sepsis; prevention of damage to organs donated for transplant prior to organ harvest; prevention of post-operative complications of cardiac surgery; short and long-term treatment of kidney failure; and drug detoxification.
MedaSorb's management team is led by Al Kraus, President and CEO, who has more than twenty-five years' experience managing companies in the dialysis, medical device products, personal computer and custom software industries. Other members of MedaSorb's management team include James Winchester, MD, CMO, Vincent Capponi, COO, and David Lamadrid, CFO.
Forward Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. MedaSorb Technologies Corporation believes that its primary risk factors include, but are not limited to: ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; obtaining government approvals, including required FDA approvals; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Current Report on Form 8-K filed with the SEC on July 6, 2006, which is available at www.sec.gov
CONTACT: Incline Partners, LLC
Andrew J. Deniken
(646) 216-8847
ajd@inclinepartners.net
RedChip Companies/Aurelius Consulting, Inc.
Bill Miller
(407) 644-4256, ext. 113
bill@aurcg.com
www.runonideas.com
www.redchip.com
RedChip Visibility Issues Research Update On MedaSorb Technologies, Inc.
ORLANDO, Fla., Jan. 10, 2007 (PRIME NEWSWIRE) -- RedChip Visibility, a division of RedChip Companies, announced today that they have issued a research update on MedaSorb Technologies (OTCBB:MSBT).
Lisa Springer, MBA/CFA, RedChip Senior Research Analyst, wrote in the report:
"MedaSorb Technologies, Inc. is developing new technologies for the purification of blood to treat both acute and chronic disease conditions. Its lead product, CytoSorb(tm), has applications in the treatment of sepsis, cardiopulmonary bypass surgery, organ donation transplantation and drug overdoses. MedaSorb filed an Investigational Device Exemption (IDE) supplement with the FDA for its CytoSorb(tm) product on January 4, 2007. The filing includes a proposed pilot study. If the pilot study is approved by the FDA, MedaSorb plans to commence clinical trials by third quarter 2007."
To receive a complimentary copy of the RedChip Research Report for MSBT, please visit: http://www.redchip.com/visibility/about.asp?page=requestMSBT…
About RedChip Visibility(tm)
RedChip Visibility, a division of RedChip Companies Inc., writes fundamental research on small-cap companies. RedChip's success has been documented in Forbes, Barron's and the Wall Street Journal. RedChip Visibility(tm) provides small-cap companies access to both professional and individual small-cap investors by holding conferences throughout the United States, producing online corporate visibility programs, and writing company sponsored research.
The RedChip Companies Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2761
RedChip Visibility Research Disclosure
Any opinions expressed herein are subject to change. RedChip Companies Inc. is an affiliate of the Aurelius Consulting Group, Inc. MedaSorb Technologies, Inc. is a client of the Aurelius Consulting Group, Inc. and of RedChip Visibility, a division of RedChip Companies. MSBT paid RedChip Visibility $34,200 for the RedChip Visibility Research Program, which includes this report. RedChip Visibility, a division of RedChip Companies, Inc., and the Aurelius Consulting Group Inc., in a joint marketing agreement, have been contracted by MedaSorb Technologies, Inc. to increase investor awareness of MSBT to the small-cap equity community. These services may include investor conferences and digital and print distribution of MSBT investor related materials. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the Aurelius Consulting Group is an investor relations firm hired by the Company and receives a monthly fee of $9,500.
CONTACT: RedChip Companies
1-800-REDCHIP
info@redchip.com
www.redchip.com
Source: PrimeZone (January 10, 2007 - 1:57 PM EST)
ORLANDO, Fla., Jan. 10, 2007 (PRIME NEWSWIRE) -- RedChip Visibility, a division of RedChip Companies, announced today that they have issued a research update on MedaSorb Technologies (OTCBB:MSBT).
Lisa Springer, MBA/CFA, RedChip Senior Research Analyst, wrote in the report:
"MedaSorb Technologies, Inc. is developing new technologies for the purification of blood to treat both acute and chronic disease conditions. Its lead product, CytoSorb(tm), has applications in the treatment of sepsis, cardiopulmonary bypass surgery, organ donation transplantation and drug overdoses. MedaSorb filed an Investigational Device Exemption (IDE) supplement with the FDA for its CytoSorb(tm) product on January 4, 2007. The filing includes a proposed pilot study. If the pilot study is approved by the FDA, MedaSorb plans to commence clinical trials by third quarter 2007."
To receive a complimentary copy of the RedChip Research Report for MSBT, please visit: http://www.redchip.com/visibility/about.asp?page=requestMSBT…
About RedChip Visibility(tm)
RedChip Visibility, a division of RedChip Companies Inc., writes fundamental research on small-cap companies. RedChip's success has been documented in Forbes, Barron's and the Wall Street Journal. RedChip Visibility(tm) provides small-cap companies access to both professional and individual small-cap investors by holding conferences throughout the United States, producing online corporate visibility programs, and writing company sponsored research.
The RedChip Companies Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2761
RedChip Visibility Research Disclosure
Any opinions expressed herein are subject to change. RedChip Companies Inc. is an affiliate of the Aurelius Consulting Group, Inc. MedaSorb Technologies, Inc. is a client of the Aurelius Consulting Group, Inc. and of RedChip Visibility, a division of RedChip Companies. MSBT paid RedChip Visibility $34,200 for the RedChip Visibility Research Program, which includes this report. RedChip Visibility, a division of RedChip Companies, Inc., and the Aurelius Consulting Group Inc., in a joint marketing agreement, have been contracted by MedaSorb Technologies, Inc. to increase investor awareness of MSBT to the small-cap equity community. These services may include investor conferences and digital and print distribution of MSBT investor related materials. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the Aurelius Consulting Group is an investor relations firm hired by the Company and receives a monthly fee of $9,500.
CONTACT: RedChip Companies
1-800-REDCHIP
info@redchip.com
www.redchip.com
Source: PrimeZone (January 10, 2007 - 1:57 PM EST)
MedaSorb Appoints Dr. Edward R. Jones, MD, MBA to Board of Directors
2007-04-11 07:30 ET - News Release
MONMOUTH JUNCTION, NJ -- (MARKET WIRE) -- 04/11/07
MedaSorb Technologies Corporation (OTCBB: MSBT) announced today the appointment of Dr. Edward R. Jones, MD, MBA to its Board of Directors, effective April 9, 2007. Dr. Jones is an attending physician at the Albert Einstein Medical Center and Chestnut Hill Hospital as well as Clinical Professor of Medicine at Temple University Hospital.
Al Kraus, President and CEO of MedaSorb Technologies Corporation, said, "Bringing Dr. Jones on board is an affirmation of our commitment to take our CytoSorb(TM) device through testing to market. His valuable experience with the research community and management of medical research programs will be a great asset to us." Dr. Jones is a practicing nephrologist as well as medical director of a dialysis facility for Fresenius Medical Care. He teaches renal pathophysiology at Temple and at the Philadelphia College of Osteopathic Medicine.
Dr. Jones is a highly respected member of the renal research community. He has published or contributed to publishing 30 chapters, articles, and abstracts on the subject of treating kidney-related illnesses. He is a sixteen-year member of the Renal Physicians Association, the Philadelphia County Medical Society and a past president of the National Kidney Foundation of the Delaware Valley. Dr. Jones has been elected as the next President of the Renal Physicians Association starting in 2008.
About MedaSorb
MedaSorb Technologies Corporation is a medical device company headquartered in Monmouth Junction, New Jersey. MedaSorb has developed and is preparing to commercialize a blood purification technology that efficiently removes toxic compounds from circulating blood. MedaSorb's initial products, CytoSorb(TM) and BetaSorb(TM), are known medically as hemoperfusion devices and incorporate proprietary adsorbent polymer technology. MedaSorb believes that potential healthcare applications for its products include: adjunctive treatment of sepsis, prevention of damage to organs donated for transplant prior to organ harvest, prevention of post-operative complications of cardiac surgery, and the short and long-term treatment of kidney failure.
2007-04-11 07:30 ET - News Release
MONMOUTH JUNCTION, NJ -- (MARKET WIRE) -- 04/11/07
MedaSorb Technologies Corporation (OTCBB: MSBT) announced today the appointment of Dr. Edward R. Jones, MD, MBA to its Board of Directors, effective April 9, 2007. Dr. Jones is an attending physician at the Albert Einstein Medical Center and Chestnut Hill Hospital as well as Clinical Professor of Medicine at Temple University Hospital.
Al Kraus, President and CEO of MedaSorb Technologies Corporation, said, "Bringing Dr. Jones on board is an affirmation of our commitment to take our CytoSorb(TM) device through testing to market. His valuable experience with the research community and management of medical research programs will be a great asset to us." Dr. Jones is a practicing nephrologist as well as medical director of a dialysis facility for Fresenius Medical Care. He teaches renal pathophysiology at Temple and at the Philadelphia College of Osteopathic Medicine.
Dr. Jones is a highly respected member of the renal research community. He has published or contributed to publishing 30 chapters, articles, and abstracts on the subject of treating kidney-related illnesses. He is a sixteen-year member of the Renal Physicians Association, the Philadelphia County Medical Society and a past president of the National Kidney Foundation of the Delaware Valley. Dr. Jones has been elected as the next President of the Renal Physicians Association starting in 2008.
About MedaSorb
MedaSorb Technologies Corporation is a medical device company headquartered in Monmouth Junction, New Jersey. MedaSorb has developed and is preparing to commercialize a blood purification technology that efficiently removes toxic compounds from circulating blood. MedaSorb's initial products, CytoSorb(TM) and BetaSorb(TM), are known medically as hemoperfusion devices and incorporate proprietary adsorbent polymer technology. MedaSorb believes that potential healthcare applications for its products include: adjunctive treatment of sepsis, prevention of damage to organs donated for transplant prior to organ harvest, prevention of post-operative complications of cardiac surgery, and the short and long-term treatment of kidney failure.
MedaSorb Technologies Corporation Begins Trading on Frankfurt Stock Exchange
2007-05-01 08:00 ET - News Release
MONMOUTH JUNCTION, NJ -- (MARKET WIRE) -- 05/01/07
MedaSorb Technologies Corporation (OTCBB: MSBT) (FRANKFURT: HQE), a medical device company that engages in the research and development of an adsorbent platform technology for removal of toxins from blood and physiologic fluids, is pleased to announce that its shares are now listed for trading on the Frankfurt Stock Exchange, effective immediately. MedaSorb's trading symbol on the Frankfurt Exchange is HQE.FSE and its WKN (German Security Code) is A0KEY3.
"Listing on the Frankfurt Exchange will allow current and potential European shareholders of MedaSorb to trade our shares within the European time zones and in local currency. This will increase our corporate profile with both private and institutional investors in Germany and across Europe," said Al Kraus, MedaSorb CEO. "This opportunity is part of our strategy to develop synergy between a global shareholder base and the commercialization of our potential products." Shares traded on the Frankfurt Stock Exchange do not have an effect on MedaSorb's total shares outstanding.
About MedaSorb
MedaSorb Technologies Corporation is a medical device company, preparing to commercialize blood purification technology that effectively removes toxic compounds from circulating blood. MedaSorb's initial products, CytoSorb(TM) and BetaSorb(TM), are known medically as hemoperfusion devices and incorporate proprietary adsorbent polymer technology. Management believes the potential healthcare applications for its products include: adjunctive treatment of sepsis, prevention of damage to organs donated for transplant prior to organ harvest, prevention of post-operative complications of cardiac surgery, and the short- and long-term treatment of kidney failure. MedaSorb is headquartered in Monmouth Junction, New Jersey.
www.medasorb.com
2007-05-01 08:00 ET - News Release
MONMOUTH JUNCTION, NJ -- (MARKET WIRE) -- 05/01/07
MedaSorb Technologies Corporation (OTCBB: MSBT) (FRANKFURT: HQE), a medical device company that engages in the research and development of an adsorbent platform technology for removal of toxins from blood and physiologic fluids, is pleased to announce that its shares are now listed for trading on the Frankfurt Stock Exchange, effective immediately. MedaSorb's trading symbol on the Frankfurt Exchange is HQE.FSE and its WKN (German Security Code) is A0KEY3.
"Listing on the Frankfurt Exchange will allow current and potential European shareholders of MedaSorb to trade our shares within the European time zones and in local currency. This will increase our corporate profile with both private and institutional investors in Germany and across Europe," said Al Kraus, MedaSorb CEO. "This opportunity is part of our strategy to develop synergy between a global shareholder base and the commercialization of our potential products." Shares traded on the Frankfurt Stock Exchange do not have an effect on MedaSorb's total shares outstanding.
About MedaSorb
MedaSorb Technologies Corporation is a medical device company, preparing to commercialize blood purification technology that effectively removes toxic compounds from circulating blood. MedaSorb's initial products, CytoSorb(TM) and BetaSorb(TM), are known medically as hemoperfusion devices and incorporate proprietary adsorbent polymer technology. Management believes the potential healthcare applications for its products include: adjunctive treatment of sepsis, prevention of damage to organs donated for transplant prior to organ harvest, prevention of post-operative complications of cardiac surgery, and the short- and long-term treatment of kidney failure. MedaSorb is headquartered in Monmouth Junction, New Jersey.
www.medasorb.com
Der Aktionär #20/07, Seite 14 (Hot Stocks für den Sommer):
Medasorb AOKEY3
Chance: *****
Risiko: *****
Ziel: 1,50 €
Stopp: 0,50 €
Medasorb AOKEY3
Chance: *****
Risiko: *****
Ziel: 1,50 €
Stopp: 0,50 €
Antwort auf Beitrag Nr.: 29.296.363 von TSX-V am 14.05.07 08:41:23Hallo TSX-V,
danke für die Info.
Mal sehen wie sich MedaSorb entwickeln wird.
OTC Klitschen sind dafür bekannt "unglaubliche" Storys zu liefern und niemand kann sie auf ihren Wahrheitsgehalt prüfen.
Gruß
Typhoon
danke für die Info.
Mal sehen wie sich MedaSorb entwickeln wird.
OTC Klitschen sind dafür bekannt "unglaubliche" Storys zu liefern und niemand kann sie auf ihren Wahrheitsgehalt prüfen.
Gruß
Typhoon
Bin bei 0,62 eingestiegen,seit dem geht es nur Berg ab,weisst jemand wie das weiter geht mit Medasorp.
Antwort auf Beitrag Nr.: 29.708.228 von Savas32 am 08.06.07 17:22:12Hallo Savas,
Ich hoffe du hast nicht zu viel Geld in Medasorb investiert.
Das Risiko hier ein Totalverlust zu erleiden ist hoch.
Gruß
Typhoon
Ich hoffe du hast nicht zu viel Geld in Medasorb investiert.
Das Risiko hier ein Totalverlust zu erleiden ist hoch.
Gruß
Typhoon
Bin auf Empfehlung eines renomierten deutschen Börsenjournals mit 10000 € eingestiegen bei 0,75 cent und habe schon einiges verloren.
Seitdem kaufe ich mir diese Zeitschrift nicht mehr.
Seitdem kaufe ich mir diese Zeitschrift nicht mehr.
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
Wertpapier | Perf. % |
---|---|
-0,87 | |
+3,04 | |
+2,54 | |
+0,49 | |
+1,77 | |
-5,47 | |
-2,02 | |
-0,16 | |
-2,89 | |
+3,88 |
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
119 | ||
74 | ||
51 | ||
49 | ||
37 | ||
35 | ||
34 | ||
34 | ||
34 | ||
32 |
14.03.24 · globenewswire · Cytosorbents |
06.03.24 · globenewswire · Cytosorbents |
08.02.24 · globenewswire · Cytosorbents |
17.01.24 · globenewswire · Cytosorbents |
28.12.23 · globenewswire · Cytosorbents |
09.11.23 · globenewswire · Cytosorbents |
27.10.23 · globenewswire · Cytosorbents |
05.10.23 · globenewswire · Cytosorbents |
27.09.23 · globenewswire · Cytosorbents |
19.09.23 · globenewswire · Cytosorbents |
Zeit | Titel |
---|---|
03.01.24 |